Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer

BACKGROUND: Tucatinib is an oral human epidermal growth factor receptor 2 (HER2)-directed therapy approved in combination with trastuzumab and capecitabine for use in patients with previously treated HER2+ metastatic breast cancer (MBC) with/without brain metastases (BM). To inform clinical decision...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Peter A., Neuberger, Edward, Schwartz, Naomi R. M., Wang, Shu, Liu, Yutong, Hsu, Ling-I, Bartley, Karen, Blahna, Matthew T., Pittner, Brian T., Wong, Gabriel, Anders, Carey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578436/
https://www.ncbi.nlm.nih.gov/pubmed/37849811
http://dx.doi.org/10.3389/fonc.2023.1264861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578436/
https://www.ncbi.nlm.nih.gov/pubmed/37849811
http://dx.doi.org/10.3389/fonc.2023.1264861

Ejemplares similares